Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00779740
Recruitment Status : Completed
First Posted : October 24, 2008
Last Update Posted : February 16, 2022
Information provided by (Responsible Party):
Organon and Co

Brief Summary:
This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis.

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Perennial Drug: mometasone furoate Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray
Actual Study Start Date : February 1, 2005
Actual Primary Completion Date : April 1, 2005
Actual Study Completion Date : April 1, 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: New Formulation Group Drug: mometasone furoate
The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088

Active Comparator: Old Formulation Group Drug: mometasone furoate
The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088

Primary Outcome Measures :
  1. Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2. [ Time Frame: After 2 weeks of treatment ]

Secondary Outcome Measures :
  1. Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching). [ Time Frame: After 2 weeks of treatment ]
  2. Overall improvement [ Time Frame: 2 weeks ]
  3. Adverse events [ Time Frame: From initial day of treatment until treatment is stopped. ]
  4. Laboratory tests [ Time Frame: At 7 or more days before treatment start, and after 2 weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of mongoloid race residing in Japan who satisfy all of the following criteria:

    • Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period.
    • Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test.
    • Outpatients who are at least 16 years of age at the time of informed consent obtained.
    • Male or female.
    • Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years).
    • Patients who can keep nasal allergy diary without fail.

Exclusion Criteria:

  • Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc.
  • Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics.
  • Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma.
  • Patients with a history of hypersensitivity to steroids or mometasone furoate.
  • Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period.
  • Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor.
  • Patients also allergic to pollen and the pollen release season occurs during the study period.
  • Patients with vasomotor rhinitis or eosinophilic rhinitis.
  • Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product.
  • Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration.
  • Patients who are participating or have participated in a clinical trial of another investigational drug within 120 days (4 months) before the day of the informed consent for this study.
  • Patients for whom the period of discontinuation of previous treatment effective for allergic rhinitis before the start of the investigational product administration is not sufficient or who cannot avoid its use.
  • Patients receiving specific desensitization therapy or nonspecific modulation therapy or who had just discontinued such therapies within 90 days (3 months) before providing consent to this study (unless such therapies are ongoing as maintenance therapy and had been started 180 days [6 months] or more before consent to this study).
  • Other patients judged inappropriate for study by the investigator or subinvestigator.
Study Data/Documents: CSR Synopsis  This link exits the site

Publications of Results:
T. Ishikawa et. al; Practica otologica. Suppl.123 Page1-18 (2008.12) -Japanese language journal

Layout table for additonal information
Responsible Party: Organon and Co Identifier: NCT00779740    
Other Study ID Numbers: P04419
First Posted: October 24, 2008    Key Record Dates
Last Update Posted: February 16, 2022
Last Verified: February 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Respiratory Tract Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents